Research and clinical use of clinical pharmacology laboratories are limited in low- and middle-income countries. We describe our experience in building and sustaining laboratory capacity for clinical pharmacology at the Infectious Diseases Institute, Kampala, Uganda.
Intervention
Existing laboratory infrastructure was repurposed, and new equipment was acquired. Laboratory personnel were hired and trained to optimise, validate, and develop in-house methods for testing antiretroviral, anti-tuberculosis and other drugs, including 10 high-performance liquid chromatography methods and four mass spectrometry methods. We reviewed all research collaborations and projects for which samples were assayed in the laboratory from January 2006 to November 2020. We assessed laboratory staff mentorship from collaborative relationships and the contribution of research projects towards human resource development, assay development, and equipment and maintenance costs. We further assessed the quality of testing and use of the laboratory for research and clinical care.
Lessons learnt
Fourteen years post inception, the clinical pharmacology laboratory had contributed significantly to the overall research output at the institute by supporting 26 pharmacokinetic studies. The laboratory has actively participated in an international external quality assurance programme for the last four years. For clinical care, a therapeutic drug monitoring service is accessible to patients living with HIV at the Adult Infectious Diseases clinic in Kampala, Uganda.
Recommendations
Driven primarily by research projects, clinical pharmacology laboratory capacity was successfully established in Uganda, resulting in sustained research output and clinical support. Strategies implemented in building capacity for this laboratory may guide similar processes in other low- and middle-income countries.
therapeutic drug monitoringbuilding laboratory capacityresource-limited settingHIVUgandaBackground
Clinical pharmacology is the study of drugs in humans.1 The central dogma of clinical pharmacology is ‘drug concentration determines drug actions’.2 Therapeutic drug monitoring (TDM) is the laboratory measurement of the drug concentration in a sample matrix.3 One of the aims of measuring drug concentrations in TDM is to adjust drug dose to optimise clinical outcomes and minimise adverse events in hard-to-manage diseases like HIV infection and other infectious diseases.3,4,5,6,7 Therapeutic drug monitoring is routinely utilised in developed countries but is used only infrequently in low- and middle-income countries (LMICs).5,8,9
Laboratories can measure drug concentrations in different sample matrices using immunoassay platforms10,11,12 and chromatographic methods like high-performance liquid chromatography (HPLC) and liquid chromatography-mass spectrometry (LC-MS).3,9 Because of its high specificity, HPLC is preferred over immunoassays, and its lower cost and local availability make it the preferred choice over LC-MS in many LMIC laboratories.13 However, both HPLC and LC-MS platforms require high technical expertise that may not be available in LMICs, and they have weak supply chains for equipment and spare parts.12 Staff training and retention are also more challenging in LMICs due to limited pre-service training opportunities and limited career options. As such, despite evidence of its relevance for specialised patient care in other settings,5 TDM is not included in the standard care package within the treatment guidelines outlined by the Uganda Ministry of Health.14
The Infectious Diseases Institute (IDI), Makerere University College of Health Sciences, is an HIV centre of excellence located in Mulago National Referral Hospital complex in Kampala, Uganda.15 The institute, established through international partnerships, is an academic research centre that commenced operations in 2002. By 2019, through its clinic in Mulago and partners, IDI was supporting 329 335 HIV-positive patients actively receiving antiretrovirals. Laboratory units in IDI included a College of American Pathologists-certified IDI clinical core laboratory and a smaller Translational Research Laboratory that was created in 2007 to develop laboratory research capacity for immunology, molecular biology, microbiology, and clinical pharmacology.
Generally, the need for a functional clinical pharmacology laboratory cannot be overlooked, especially in settings with a high disease burden like LMICs. Efforts to enhance clinical pharmacology laboratory capacity must consider multifaceted needs, including human resources, knowledge building, and infrastructure.16,17,18 Across its programming, IDI uses a systematic approach (Capacity Pyramid) to highlight gaps in interdependent types of capacity – both personal (e.g. skills) and institutional (e.g. systems) – and inform comprehensive interventions.19 Furthermore, collaborative partnerships between institutions in developing and developed countries have been used as a key strategy to address challenges in strengthening laboratory capacity.9,16,18 This article describes IDI’s experience with developing capacity by establishing and sustaining a clinical pharmacology laboratory in Uganda.
Description of the interventionEthical considerations
Ethics committee approval was not required for this research. This research involved no human or animal subjects.
Repurposing of existing laboratory infrastructure
In a clinical pharmacology laboratory for TDM, the process workflow is critical for assay accuracy and should be considered in the design of the laboratory facility.20 Between January 2007 and December 2008, 292.53 square feet of space in the Translational Research Laboratory was repurposed to host the clinical pharmacology laboratory. Two fume extractors (to eliminate toxic chemical fumes for personnel health and safety) and one fume hood (for specific sample processing and storage) were already existent before the laboratory was repurposed. A lighting system akin to natural light was installed to ease visibility.
Strong workbenches made of non-porous material were already available in the acquired Translational Research Laboratory, and these were arranged for smooth workflow and to support the instruments. Air conditioning and air filtration systems were also already installed in the acquired laboratory space; these helped minimise dust exposure and ensure ambient temperature for the instruments and laboratory personnel. Constant laboratory operation was supported by both the national electric power supply and a backup generator installed at the IDI in 2004.
Laboratory equipment acquisition
Two HPLC-Ultraviolet (HPLC-UV) machines with inbuilt detectors, an autosampler, and pumps (Shimadzu LC-2010CHT, Shimadzu, Kyoto, Japan) controlled by CLASS-VP software version 6.1 (Shimadzu, Kyoto, Japan) were installed in the laboratory (Figure 1). The machines were obtained as generous donations from Trinity College Dublin in 2007 and the University of Zurich in 2013. With internally generated funds, the laboratory acquired other primary instruments like an analytical balance, a pH meter, and a magnetic stirrer. The laboratory also received a generous donation of a centrifuge from the United States National Institutes of Health.
High-performance liquid chromatography-ultraviolet detection machines installed in the clinical pharmacology laboratory at the Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda between 2007 and 2013.
In 2018, leveraging its relationship with the University of Zurich, IDI received a donation of an LC-MS machine (Thermo Scientific LCQ Fleet ion trap LC/MSn model, Thermo Fisher Scientific, San Jose, California, United States), the first of its kind in Uganda for TDM and pharmacological research (Figure 2). Subsequently, in 2019, a nitrogen generator was purchased (Figure 3) to support the operations of the LC-MS. A technical service engineer (originally from South Africa, but subsequently from within Uganda) authorised by the manufacturer services the HPLC-UV instruments biannually. Trained IDI laboratory staff service the LC-MS with expert guidance from the University of Zurich. Also, IDI engineers based at the site oversee the periodic servicing of other laboratory equipment, including the analytical balance, centrifuge, and pH meter.
A liquid chromatography-mass spectrometry instrument installed in the clinical pharmacology laboratory at the Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda in 2018.
A nitrogen generator installed to support continuous nitrogen gas supply to the mass spectrometer in the clinical pharmacology laboratory at the Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda in 2019.
Laboratory human resource developmentHuman resource establishment
Quality human resource, which is an important aspect of local capacity, is the centre of most laboratory capacity-building programmes.16,17,21,22,23 Establishing quality human resource reduces both appraisal and failure costs, thereby reducing the overall cost of quality, which is a burden in LMICs.24 Building on the quality of the Makerere University-Johns Hopkins University collaboration that led to the establishment of a College of American Pathologists-Certified laboratory, two laboratory technologists that had rotated through the IDI clinical core laboratory were recruited.
Human resource knowledge building
During the establishment phase, two laboratory technologists were trained in methods for measuring drug concentrations using the HPLC instrument, one at the University of Cape Town and the other at both Radboud University and the University of Zurich. In 2018, through the strong IDI-University of Zurich research collaboration, one staff member was further trained in the use of the LC-MS platform, leading to the donation of the equipment to IDI. The training activities were conducted both physically and via virtual media platforms to expand knowledge and skills in the areas of sample processing and measurement of drug concentrations in different human sample matrices, results analysis, equipment operation and maintenance, method development and validation, and the supply chain process. Using cascade training (Table 1), the formally trained staff member trained five other laboratory technologists to expand the laboratory’s human resource capacity. Continuing medical education was encouraged for the laboratory staff throughout the capacity-building programme at the IDI. Currently, the laboratory has a strong human resource capacity composed of three laboratory technologists and continues to get technical and mentorship support from the University of Zurich.
Human resource training programmes conducted between 2006 and 2019.
Year
Number of staff
Training site
Training period (for external training)
Assay platform
2019††
2
On-site and UZH, Zurich, Switzerland
2 Weeks
LC-MS
2018‡
2§
On-site and UZH, Zurich, Switzerland
1 Mzonth
LC-MS¶
2017‡
1
On-site
-
HPLC-UV
2015‡
2§
On-site and UZH, Zurich, Switzerland
1 Month
HPLC-UV
2014‡
2§
On-site and UZH, Zurich, Switzerland
1 Month
HPLC-UV
2013‡
1
On-site
-
HPLC-UV
2012
1
UZH, Zurich, Switzerland
2 Weeks
HPLC-UV
2011
1
Radboud University, Nijmegen, Netherlands
2 Weeks
HPLC-UV
2011†
1
On-site
1 Month
HPLC-UV
2006
1
University of Cape Town, Cape town, South Africa
1 Month
HPLC-UV
, Cascade training achieved to the second employee.
, One employee that trained at UZH trained another employee on-site.
, One employee trained another employee on-site while training at UZH.
, After attaining required human resource capacity, the LC-MS was acquired through IDI-University of Zurich research collaborative partnership.
, Expert visit and training at the clinical pharmacology laboratory at IDI.
UZH, University of Zurich; IDI, Infectious Diseases Institute; LC-MS, liquid chromatography-mass spectrometry; HPLC-UV, high-performance liquid chromatography-ultraviolet detection.
Lessons learntCurrent capacity for drug concentration measurementsPharmacokinetic assays
A clinical pharmacology laboratory was developed at IDI and currently has the capacity to measure drug concentrations to guide TDM and clinical pharmacology studies using 10 analytical methods for HPLC-UV and six methods for LC-MS either simultaneously or singly. These methods are used to measure the concentrations of anti-tuberculosis drugs such as ethambutol, rifampicin, isoniazid, pyrazinamide, rifapentine, rifabutin and moxifloxacin. Antiretroviral drugs analysed in the laboratory include nevirapine, efavirenz, atazanavir, lopinavir, tenofovir, saquinavir, darunavir, etravirine, dolutegravir and raltegravir. Antiepileptics (phenytoin and carbamazepine), antibiotics (vancomycin, gentamicin, kanamycin and amikacin), and antimalarial drugs (lumefantrine, artemether and its metabolites and halofantrine) are also analysed in the laboratory.
Currently, the LC-MS methods are used to determine the concentrations of tenofovir, dolutegravir, amikacin, and antimalarial drugs, while the concentrations of other drugs are measured using HPLC-UV. The laboratory staff can also execute in-house innovations to develop, validate, and optimise methods for measuring the concentration of several drugs using the HPLC-UV and LC-MS. Drug concentration data from the laboratory has enabled researchers working on pharmacokinetic studies to detect drug interactions and sub-therapeutic concentrations and monitor patient antiretroviral therapy adherence (Table 2).
Pharmacokinetic studies formally supported by the clinical pharmacology laboratory at the Infectious Diseases Institute in Kampala, Uganda between 2009 and 2015.
Study
Year
Population
Analyte
No. of samples tested
‘Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin.’25
2009
HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin
Nevirapine
254
‘Therapeutic drug monitoring of nevirapine in saliva in Uganda using high-performance liquid chromatography and a low cost thin-layer chromatography technique.’13
2012
HIV-infected Ugandan adults on nevirapine-based antiretroviral therapy
Nevirapine
587
‘High efavirenz serum concentrations in TB/HIV-co-infected Ugandan adults with a CYP2B6 516TT genotype on anti-TB treatment.’26
2013 to 2015
Tuberculosis/HIV-co-infected patients on rifampicin-based anti-tuberculosis therapy and antiretroviral therapy, including 600 mg of efavirenz
Efavirenz
333
‘Study on outcomes related to tuberculosis and HIV drug concentrations in Uganda (South).’27
2013 to 2015
HIV/tuberculosis-co-infected adults with a diagnosis of their first episode of pulmonary tuberculosis
Isoniazid, pyrazinamide, rifampicin and ethambutol
6003
‘Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: A case control study.’15
2015
Patients on any first-line or second-line antiretroviral therapy regimen for at least 6 months
Efavirenz, nevirapine, atazanavir, lopinavir.
573
Laboratory quality assurance programme
In 2017, the laboratory commenced its participation in an external quality assurance (EQA) programme for nevirapine, efavirenz, atazanavir, and lopinavir through the Stichting Kwaliteitsbewaking Klinische Geneesmiddelanalyse en Toxicologie (KKGT) (Association for Quality Assessment in Therapeutic Drug Monitoring and Clinical Toxicology, Amstelveen, the Netherlands).28 The EQA samples analysed in 2017 and 2019 were within the KKGT acceptance range in the four annual rounds. In 2018, EQA test results were within the KKGT acceptance range except for atazanavir in round one, lopinavir in rounds two and three, and efavirenz in round four.
In 2019, anti-tuberculosis drugs, including ethambutol, rifampicin, isoniazid, pyrazinamide, rifapentine, and rifabutin, were included in two annual rounds of the EQA programme. The first attempt yielded results within the KKGT acceptance range in both rounds for all anti-tuberculosis drugs except isoniazid in round two. The second attempt in 2020 was not conducted for anti-tuberculosis drugs due to interruptions in the shipment of the EQA samples to the laboratory.
Antibiotics (only amikacin and vancomycin) and antiepileptics (only phenytoin and carbamazepine) were included in the 2017 EQA subscription, with four annual rounds. Attempts to analyse the antiepileptics in all four rounds yielded results that were outside the KKGT acceptable range. After laboratory preparations, vancomycin was included in the EQA programme in 2020 and yielded results within the KKGT acceptance range in rounds one and four. However, the vancomycin EQA results for rounds two and three were out of the KKGT acceptance range. Amikacin was not tested together with vancomycin in the EQA programme because the method to measure amikacin concentrations in the laboratory was not developed until 2020.
With mutual interdependence with collaborators, the laboratory continues to develop capacity for other KKGT programmes, with continuous optimisation of existing assays for the measurement of drugs like the antiepileptics for which measurement was unsuccessful in the previous attempts. The lack of research studies requiring the measurement of carbamazepine and phenytoin concentrations may have contributed to the lesser focus on the antiepileptics programme. The EQA helped laboratory staff to identify pitfalls in routine laboratory analyses. Interference of other analytes with the KKGT EQA samples was found to be the major cause of out-of-range low scores in the antiretroviral programme. This challenge was corrected by optimising the methods for simultaneous measurement of efavirenz, lopinavir, and atazanavir and using a different analytical method that had no interference between analytes. Generally, participation in the EQA scheme improved staff confidence in supporting research studies and clinicians seeking TDM services.
Laboratory support for therapeutic drug monitoring and the need for a clinical pharmacology laboratory
Clinicians and clinical researchers at the IDI clinic and external institutions have successfully used drug concentration results from the laboratory for TDM, specifically to assess non-adherence to regimens or to switch or discontinue patient therapy because of suspected drug resistance and toxicities. Clinicians obtain patients’ blood samples and send the harvested plasma to the clinical pharmacology laboratory for testing with a corresponding request form attached. Results from the laboratory are returned to clinicians to inform clinical management (counselling or dose adjustment, where appropriate). Cumulatively, the laboratory tested 181 clinical care samples from the Adult Infectious Diseases Clinic at the IDI between 2013 and 2019. With this support for clinical management, the need for a clinical pharmacology laboratory cannot be overemphasised, especially in LMICs where there is a high disease burden.
Challenges and solutions encountered during laboratory capacity-building processes
The instruments used for drug concentration measurements are costly and were acquired free of charge to IDI through international collaborations (grants and donations). Nevertheless, the costs of equipment preventive maintenance remained a challenge because of the high costs of service vendors and spare parts. The laboratory was able to incorporate these costs within research project budgets over the years, including from competitive grants. Uganda has only a few authorised vendors that supply genuine high-purity reagents of HPLC and LC-MS grade, and these are also costly to procure. Before the acquisition of a nitrogen gas generator, obtaining high-purity gases like nitrogen and helium was difficult. Initial training of laboratory technologists was limited to two staff members since this had to be conducted overseas. Fortunately, efforts to cascade training to other laboratory staff were successful at minimal costs. Notably, these challenges raise the cost of measuring the concentration of a drug in a single sample to approximately $40 United States dollars, which is outside the reach of many patients. From inception, the laboratory’s business case has thus focussed on funded research and clinic projects. For example, the TDM services at the IDI clinic had to be paused in 2019, after analysing 181 samples from clinic patients, due to funding constraints. However, the clinical pharmacology laboratory remained operational since no such laboratory supporting clinical care was established in the country.
Recommendations
The strategies employed in our laboratory yielded tangible results similar to those observed in related laboratory capacity-building programmes.16,17,18,22,23,29,30 Clinical pharmacology laboratory capacity was developed to measure concentrations of antiretrovirals, anti-seizures, antibiotics, antimalarials, and anti-tuberculosis drugs for TDM. The capacity to develop, validate, and optimise analytical methods for other drugs was also developed. The success recorded for this laboratory capacity-building process reflects the gradual progress to strengthen capacity from inception to date with collaborative support. The focus of the institution’s research programme in the field of pharmacokinetics was sustained over the years, enabling continuous cash flow to the laboratory in the form of research costs covering sample analysis. However, with short-term project support as the main source of laboratory resources, factors beyond the laboratory’s direct control such as grant success or availability of collaborators with aligned goals could lead to shocks in the near term and impair long-term sustainability. We therefore recommend that laboratories in LMICs (and their parent institutions) must be prepared to strengthen and sustain results from collaborative programmes when external support ends.
Laboratories in LMICs intending to build and sustain long-term capacity for clinical pharmacology should build local capacity through training and infrastructure development.16,17,18,31 As with other capacity-building programmes, staff training in our setting was challenging,16,31 requiring international travel and time off work. We further recommend the introduction of practical coursework for clinical pharmacology sessions in pre-service laboratory education (bachelor’s degree-level laboratory technology training) to ease future on-the-job staff training. The African Field Epidemiology Track programme developed and adopted this strategy, positively changing the laboratory profession in its programme member countries.17,32 Using established centres like IDI for postgraduate training in pharmacology or for placements to support new laboratories could reduce costs associated with expensive international training. Further, pharmacology postgraduates can be included in laboratory mentorship programmes in LMICs.
Investment in appropriate infrastructure at inception not only promotes staff safety but can also prolong the lifespan of the equipment. High-level air conditioning mitigates challenges of hot and humid climates that may affect laboratory instruments. The use of fume extractors to eliminate environmental dust and toxic fumes from laboratory reagents and processes is essential for staff health and safety. Laboratory fume hoods should be used together with proper reagent segregation to minimise the chances of explosions resulting from flammable reagent fume reactions.
The outcomes presented in this article represent success at a site where clinical research and laboratory infrastructure were already present and operating to international standards at baseline. Our experience may thus not apply to all LMICs due to variations in local guidelines and socio-economic factors. A clinical pharmacology laboratory was established, and laboratory capacity was developed and sustained at the IDI through strong capacity-building collaborative relationships. The laboratory significantly contributed to research capacity development at IDI and other external institutions by providing answers to questions from several pharmacology research studies. Building clinical pharmacology laboratory capacity in LMICs is feasible and necessary to support the global goal of managing HIV infection and other diseases.
Acknowledgements
We acknowledge Peter Smith, University of Cape Town, Lance Heinle, Pfizer Global Health Fellows Program, and David M. Burger, Nijmegen, Radboud University, for organising staff training.
Competing interests
The authors declare that they have no financial or personal relationships that may have inappropriately influenced them in writing this article.
Authors’ contributions
D.O. and A.B. contributed equally. C.M. and DM. contributed equally.
D.O. and A.B. conceived and designed the concept. D.O. wrote the initial manuscript. D.O., A.B., R.K., P.B.-K., R.N., J.M., O.M., E.M., D.N., P.E., B.C., Y.C.M., M.L., D.M., and C.M. participated in critical revisions of the manuscript for intellectual content. C.S.-W., P.B.-K., U.G., M.L., D.M., and C.M. gave mentorship and technical support. O.M., J.F., D.N., B.C., Y.C.M., P.E., K.M., and A.K. participated in administrative support. All named authors approved the final manuscript for publication.
Sources of support
We are grateful to Realta Foundation, the Irish Department for Foreign Affairs, and the Health Research Board of Ireland (GHRA06/02, GHRA07/09) for initial support to establish the laboratory. We acknowledge the support given by the University of Zurich in the provision of equipment and staff training. We acknowledge funding support for equipment, supplies, and maintenance from the European and Developing Countries Clinical Trials Partnership and World Health Organization Tropical Diseases Research (CSA-Ebola-2015-353).
D.O. is supported by the Fogarty International Center of the National Institutes of Health under Award Number D43TW009771. A.B. is currently a PhD scholar supported through the Fogarty International Centre, National Institute of Health grant #2D43TW009771-06 ‘HIV and co-infections in Uganda’. The authors also acknowledge the DELTAS Africa-funded Makerere Uganda Virus Research Institute Infection and Immunity (MUII) programme (Grant #107743/Z/15/Z) that has collaborated with IDI in building capacity of the Translational Research Laboratory. We thank the United States National Institutes of Health for the generous donation of a centrifuge to the laboratory. R.K. is currently a PhD scholar supported through the DELTAS Africa Initiative grant #DEL-15-011 to THRiVE-2, from Wellcome Trust grant #107742/Z/15/Z and the United Kingdom government. E.M. is currently a MSc fellow supported through the United States National Institutes of Health – Fogarty International Center, BrecA grant #1U2RTW010672. M.L. is supported by European and Developing Countries Clinical Trials Partnership (RIA2018EF-2083) which is part of the European and Developing Countries Clinical Trials Partnership programme supported by the European Union’s Horizon 2020 Research and Innovation Program.
Data availability
All data underlying the findings are fully available without restriction in the manuscript from the corresponding author (D.O.).
Disclaimer
The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated. The views and opinions of authors expressed herein do not necessarily state or reflect those of European and Developing Countries Clinical Trials Partnership.
ReferencesHuangS-M, LertoraJJ, MarkeySP, AtkinsonAJ, Jr. Principles of clinical pharmacology. San Diego, California: Academic Press; 2012.HolfordNH, AtkinsonAJ, Jr. Time course of drug response. In: AJAtkins, DRAbernethy, CEDaniels, RLDedrick, SPMarkey, editors. Principles of clinical pharmacology. Bethesda, Maryland: Elsevier, 2007; pp. 301–311. https://doi.org/10.1016/B978-012369417-1/50059-6KangJS, LeeMH. Overview of therapeutic drug monitoring. Korean J Intern Med. 2009;24(1):1–10. https://doi.org/10.3904/kjim.2009.24.1.1GutiérrezF, NavarroA, PadillaS, et al. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis. 2005;41(11):1648–1653. https://doi.org/10.1086/497835SchoenenbergerJA, AragonesAM, CanoSM, et al. The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems. Ther Drug Monit. 2013;35(1):71–77. https://doi.org/10.1097/FTD.0b013e3182791f8cHallworthM, WatsonI. Therapeutic drug monitoring: Clinical guide. Abbot park, Illinois: Abbott Laboratories; 2010.GhiculescuR. Therapeutic drug monitoring: Which drugs, why, when and how to do it. Aust Prescr2008;31:42–4. https://doi.org/10.18773/austprescr.2008.025MelkerR, SackellaresJ, GoldM. System and method for therapeutic drug monitoring. Gainesville, US: University of Florida Research Foundation Inc.; 2005.NwobodoN. Therapeutic drug monitoring in a developing nation: A clinical guide. JRSM Open. 2014;5(8):2054270414531121. https://doi.org/10.1177/2054270414531121HicksJM, BrettEMJ. Falsely increased digoxin concentrations in samples from neonates and infants. Ther Drug Monit. 1984;6(4):461–464. https://doi.org/10.1097/00007691-198412000-00015PatelJA, ClaytonLT, LeBelCP, McClatcheyKDJ. Abnormal theophylline levels in plasma by fluorescence polarization immunoassay in patients with renal disease. Ther Drug Monit. 1984;6(4):458–460. https://doi.org/10.1097/00007691-198412000-00014TouwDJ, NeefC, ThomsonAH, VinksAAJ. Cost-effectiveness of therapeutic drug monitoring: A systematic review. Ther Drug Monit. 2005;27(1):10–17. https://doi.org/10.1097/00007691-200502000-00004LamordeM, FillekesQ, SigaloffK, et al. Therapeutic drug monitoring of nevirapine in saliva in Uganda using high performance liquid chromatography and a low cost thin-layer chromatography technique. BMC Infect Dis. 2014;14:473. https://doi.org/10.1186/1471-2334-14-473Ministry of Health. Consolidated guidelines for prevention and treatment of HIV in Uganda. Kampala: Ministry of Health; 2016.BuzibyeA, MusaaziJ, Von BraunA, et al. Antiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: A case control study. AIDS Res Ther. 2019;16(1):1–5. https://doi.org/10.1186/s12981-019-0255-xHamelDJ, SankaléJ-L, SamuelsJO, et al. Building laboratory capacity to support HIV care in Nigeria: Harvard/APIN PEPFAR, 2004–2012. Afr J Lab Med. 2015;4(1):190. https://doi.org/10.4102/ajlm.v4i1.190MasanzaMM, NqobileN, MukangaD, GittaSNJ. Laboratory capacity building for the International Health Regulations (IHR [2005]) in resource-poor countries: The experience of the African Field Epidemiology Network (AFENET). BMC Public Health. 2010;10(1):1–7. https://doi.org/10.1186/1471-2458-10-S1-S8ParamasivanC, LeeE, KaoK, et al. Experience establishing tuberculosis laboratory capacity in a developing country setting. Int J Tuberc Lung Dis. 2010;14(1):59–64.PotterC, BroughR. Systemic capacity building: A hierarchy of needs. Health Policy Plan. 2004;19(5):336–345. https://doi.org/10.1093/heapol/czh038National Research Council. Laboratory design, construction, and renovation: Participants, process, and product. Washington, DC: National Academies Press; 2000.FitzgibbonJE, WallisCL. Laboratory challenges conducting international clinical research in resource-limited settings. J Acquir Immune Defic Syndr. 2014;65(Suppl. 1 [0 1]):S36–S39. https://doi.org/10.1097/QAI.0000000000000038MapongaCC, Monera-PendukaTG, MtisiTJ, et al. Two decades (1998 to 2018) of collaborative human immunodeficiency virus clinical pharmacology capacity building in a resource constrained setting. Cost Eff Resour Alloc. 2021;19(1):1–8. https://doi.org/10.1186/s12962-021-00327-yMtisiTJ, MapongaC, Monera-PendukaTG, et al. Strategic establishment of an International Pharmacology Specialty Laboratory in a resource-limited setting. Afr J Lab Med. 2018;7(1):1–6. https://doi.org/10.4102/ajlm.v7i1.659ElbireerA, GableAR, JacksonJBJ. Cost of quality at a clinical laboratory in a resource-limited country. Lab Med. 2010;41(7):429–433. https://doi.org/10.1309/LMCZ0ZFR80QWIBEMLamordeM, Byakika-KibwikaP, Okaba-KayomV, et al. Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. J Antimicrob Chemother. 2011;66(1):180–183. https://doi.org/10.1093/jac/dkq411Von BraunA, CastelnuovoB, LedergerberB, et al. High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatment. J Antimicrob Chemother. 2019;74(1):135–138. https://doi.org/10.1093/jac/dky379Sekaggya-WiltshireC, CastelnuovoB, Von BraunA, et al. Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: Design, methods and patient characteristics of the SOUTH study. BMJ Open. 2017;7(9):e014679. https://doi.org/10.1136/bmjopen-2016-014679DrosteJ, AarnoutseRE, KoopmansPP, HeksterYA, BurgerDMJ. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr. 2003;32(3):287–291. https://doi.org/10.1097/00126334-200303010-00007NiyonzimaN, WannumeH, KadhumbulaS, et al. Strengthening laboratory diagnostic capacity to support cancer care in Uganda. Am J Clin Pathol. 2021;156(2):205–213. https://doi.org/10.1093/ajcp/aqaa218PagliaMG, BevilacquaN, HajiHS, et al. Improvement of tuberculosis laboratory capacity on pemba island, zanzibar: A health cooperation project. PLoS One. 2012;7(8):e44109. https://doi.org/10.1371/journal.pone.0044109PettiCA, PolageCR, QuinnTC, RonaldAR, SandeMA. Laboratory medicine in Africa: A barrier to effective health care. Clin Infect Dis. 2006;42(3):377–382. https://doi.org/10.1086/499363GittaSN, MukangaD, BabiryeR, DahlkeM, TshimangaM, NsubugaP. The African Field Epidemiology Network-Networking for effective field epidemiology capacity building and service delivery. Pan Afr Med J. 2011;10(Suppl. 1):3.
How to cite this article: Omali D, Buzibye A, Kwizera R, et al. Building clinical pharmacology laboratory capacity in low- and middle-income countries: Experience from Uganda. Afr J Lab Med. 2023;12(1), a1956. https://doi.org/10.4102/ajlm.v12i1.1956